In the clinical trial working experience with Xyrem in narcolepsy/cataplexy patients at therapeutic doses, two patients claimed nervousness and one documented insomnia subsequent abrupt discontinuation for the termination of the clinical demo; in The 2 patients with anxiousness, the frequency of cataplexy had enhanced markedly concurrently.As well